1. Ogawa T, Shichino S, Ueha S, Ogawa S, Matsushima K.Complement protein C1q activates lung fibroblasts and exacerbates silica-induced pulmonary fibrosis in mice. Biochem Biophys Res Commun. 2022 7;603:88-93. doi: 10.1016/j.bbrc.2022.02.090
2. Saitoh A, Nagayama Y, Yamada D, Makino K, Yoshioka T, Yamanaka N, Nakatani M, Takahashi Y, Yamazaki M, Shigemoto C, Ohashi M, Okano K, Omata T, Toda E, Sano Y, Takahashi H, Matsushima K, Terashima Y. Disulfiram Produces Potent Anxiolytic-Like Effects Without Benzodiazepine Anxiolytics-Related Adverse Effects in Mice. Front Pharmacol. 2022 7;13:826783. doi: 10.3389/fphar.2022.826783
3. Yasui F, Matsumoto Y, Yamamoto N, Sanada T, Honda T, Munakata T, Itoh Y, Kohara M. Infection with the SARS-CoV-2 B.1.351 variant is lethal in aged BALB/c mice. Sci Rep. 2022 9;12(1):4150. doi: 10.1038/s41598-022-08104-4
4. Furukawa R, Kitabatake M, Ouji-Sageshima N, Suzuki Y, Nakano A, Matsumura Y, Nakano R, Kasahara K, Kubo K, Kayano SI, Yano H, Ito T. Persimmon-derived tannin has antiviral effects and reduces the severity of infection and transmission of SARS-CoV-2 in a Syrian hamster model. Scientific Reports. 2021, 11, 23695. doi: 10.1038/s41598-021-03149-3
5. Tomomi Akita, Ryosuke Kimura, Saki Akaguma, Mio Nagai, Yusuke Nakao, Mamiko Tsugane, Hiroaki Suzuki, Jun-Ichiro Oka, Chikamasa Yamashita*.Usefulness of cell-penetrating peptides and penetration accelerating sequence for nose-to-brain delivery of glucagon-like peptide-2. Journal of Controlled Release. 2021. 335:575-583. doi:10.1016/j.jconrel.2021.06.007
6. Yokoyama A, Sakamoto Y, Jo T, Urushiyama H, Tamiya H, Tanaka G, Matsui H, Fushimi K, Yasunaga H, Nagase T. Pulmonary disease as a risk factor for transfusion-related acute lung injury.ERJ Open Res. 2021 Aug 31;7(3):00039-2021. doi: 10.1183/23120541.00039-2021
7. Amano Y, Kage H, Tanaka G, Gonoi W, Nakai Y, Kurokawa R, Inui S, Okamoto K, Harada S, Iwabu M, Morizaki Y, Abe O, Moriya K, Nagase T.Diagnostic prediction of COVID-19 based on clinical and radiological findings in a relatively low COVID-19 prevalence area.Respir Investig. 2021 Jul;59(4):446-453. doi: 10.1016/j.resinv.2021.03.002